Abstract 183P
Background
In cancer, inflammation frequently coexists with hypoxia within the tumor microenvironment (TME), often creating an immunosuppressive environment. This hostile milieu is further exacerbated by acidosis, which collectively further hinders effective anti-tumor immune responses. Carbonic anhydrase IX (CAIX) is a well-established hypoxia marker that plays a key role in the pH regulation and adaptation of tumor cells to hypoxia resulting in tumor progression. The CAIX activity contributes to the formation of an acidic environment, which can suppress the function of cytotoxic T cells and other immune cells. While primarily induced by HIF1α under hypoxic conditions, CAIX expression can also be triggered in an inflammatory milieu by IL6 or the COX-2/PGE2 pathway. The goal of this study is to determine the role of CAIX in the regulation of inflammatory and anti-tumor immune responses.
Methods
CAIX+ and CAIX-silenced HT1080 cells were cultured in the presence of a conditioned (inflammatory) medium obtained from MUF spheroids (MUF-CM) under normoxic or hypoxic conditions. RNA samples were analyzed by Clariom, followed by unsupervised clustering. Gene Set Expression Analysis (GSEA) was used to analyze the gene expression. The relation between CAIX level and gene sets identified by GSEA was also analyzed in TCGA SARComa samples and pancreatic cancer (PC).
Results
We found that MUF-CM can upregulate CAIX expression in fibrosarcoma and PC cells even under normoxia. Our analysis revealed that suppression of CAIX leads to upregulation of hallmarks of IFN-α, IFN-γ, and inflammatory response. In silico analysis of TCGA SARC samples confirmed the relationship between lower CAIX expression and higher expression of IFN-α, IFN-γ and inflammation response gene sets, which predicted better overall survival. Moreover, the immune gene sets associated with immune activation and expression of HLA-antigens negatively correlated with CAIX.
Conclusions
Understanding the complex interplay between hypoxia, CAIX, and inflammation is crucial for developing effective cancer treatments. Given the central role of CAIX in this intricate relationship, targeting the function of this enzyme may represent a new opportunity to create a favorable milieu for anti-tumor immune response in the TME.
Legal entity responsible for the study
The authors.
Funding
The Slovak Research and Development Agency 20-0480.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
21P - Impact of TP53 mutation subtypes on the efficacy of anti-PD-(L)1 immunotherapy in patients with non-small cell lung cancer
Presenter: Lige Wu
Session: Poster Display session
Resources:
Abstract
22P - Extracellular vesicles as predictive biomarkers for chemoimmunotherapy in biliary tract cancer
Presenter: Michele Zanoni
Session: Poster Display session
Resources:
Abstract
23P - Non-small cell lung cancer DNA methylation profiles correlate with immune checkpoint inhibitor response
Presenter: Julia Berger
Session: Poster Display session
Resources:
Abstract
24P - Blood DNA methylation profiles in NSCLC patients treated with immune checkpoint inhibitors
Presenter: Markus Kleinberger
Session: Poster Display session
Resources:
Abstract
25P - Circulating tumor DNA is predictive of overall survival in patients with metastatic uveal melanoma
Presenter: Egle Ramelyte
Session: Poster Display session
Resources:
Abstract
26P - Liquid biopsy-based percision immunotherapy: CCAT1 and HEIH lncRNAs identify young breast cancer patients likely to respond to PD-L1 blockade
Presenter: Rana Youness
Session: Poster Display session
Resources:
Abstract
27P - Single cell RNA sequencing (scRNAseq) analysis of peripheral immune cell populations from patients treated with anti-PD1 with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
Presenter: Séverine Carlier
Session: Poster Display session
Resources:
Abstract
28P - Circulating biomarkers in non-small cell lung cancer patients treated with immune checkpoint inhibitors
Presenter: Paola Ulivi
Session: Poster Display session
Resources:
Abstract
29P - Prognostic value of systemic inflammatory index and platelet-to-lymphocyte ratio in muscle-invasive bladder cancer patients treated with neoadjuvant chemo-immunotherapy in the AURA trial
Presenter: Jeremy Blanc
Session: Poster Display session
Resources:
Abstract
30P - The prognostic value of low density neutrophils in breast cancer: Implications for therapeutic strategies
Presenter: Telma Martins
Session: Poster Display session
Resources:
Abstract